GENE ONLINE|News &
Opinion
Blog

Alnylam Pharmaceuticals
FDA Approves Alnylam’s Rare Disease RNAi Therapeutic
2022-06-15
Alnylam Challenges Moderna and Pfizer with Patent Infringement
2022-03-18
Novartis Teams Up with Alnylam to Explore Targeted Liver Therapies
2022-01-07
Is the Race On for RNAi? A Chinese Pharma’s $450M Deal May Just Be the Start
2021-10-13
Top Announcements from the J.P. Morgan Healthcare Conference 2021
2021-01-13
Alnylam Aims to Obtain “Top 5 Biotech” Tag By 2025
2021-01-12
Alnylam Nears Fourth Approval with Successful Trial Data for RNAi Drug
2021-01-08
Alnylam Receives FDA Nod for its Third Rare Disease Drug
2020-11-25
Intellia Trials CRISPR Drug as Permanent Cure to Fatal Hereditary Disease
2020-10-21
R&D
Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
2020-08-17
Alnylam’s RNAi-Based Therapy Lumasiran Impresses in Phase 3 Primary Hyperoxaluria Trials
2020-06-12
GIVLAARI to Enter European Market Following EMA Approval
2020-03-04
JP Morgan Healthcare Conference 2020 Updates
2020-01-16
The 38th Annual J.P. Morgan Healthcare Conference – What to Expect?
2020-01-13
FDA approves second RNAi based drug
2019-11-20
LATEST
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
Scroll to Top